NCT06646341 EMVI as a Determinant of Metastasis in Colorectal Cancer
| NCT ID | NCT06646341 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Imperial College London |
| Condition | Colo-rectal Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2023-01-01 |
| Primary Completion | 2025-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100 participants in total. It began in 2023-01-01 with a primary completion date of 2025-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Bowel cancer is the fourth most commonly occurring cancer and the second highest cause of cancer deaths in the UK. Despite advances in treatment, over 40% of patients will die within 5 years. This is normally due to spread of the cancer to other organs (called metastases). Much of the current research focuses on use of additional treatments such as radiotherapy and chemotherapy before or after surgery (adjuvant treatment). It is of vital importance that patients who would benefit from adjuvant treatment can be accurately identified. At the moment, the system used locally to do this places emphasis on the presence of affected lymph nodes (glands). This is because doctors believe that cancer spreads to other organs through the lymphatic system. However, recent studies have suggested that this is not the case. It is believed that cancer spreads to other organs through the blood stream rather than the lymph node system. This research will look at the genetic material in tumours and metastases as well as in areas of blood vessel invasion and lymph nodes. The analysis will allow us to build a 'family tree' of the tumour and allow us to map the pathway by which the tumour spreads. Tissue samples already collected through a patient's routine care will be used for this study. If the spread through the blood vessels is proven, this would change the way in which patients are selected for treatment and allow development of new treatments to target these pathways.
Eligibility Criteria
Inclusion Criteria: 1. Are aged 16 years or over with colorectal cancer 2. Colon / rectum has been surgically removed 3. Distant metastases has been surgically removed 4. Pre operative staging in the form of CT/MRI has been undertaken and images available for review Exclusion Criteria: 1. Pathological complete response in the primary tumour 2. Local resection of the primary tumour 3. Inadequate quantity of tissue sample to perform analyses
Contact & Investigator
Gina Brown, MD
PRINCIPAL INVESTIGATOR
Imperial College London
Frequently Asked Questions
Who can join the NCT06646341 clinical trial?
This trial is open to participants of all sexes, aged 16 Years or older, up to 100 Years, studying Colo-rectal Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06646341 currently recruiting?
Yes, NCT06646341 is actively recruiting participants. Contact the research team at c.martin1@imperial.ac.uk for enrollment information.
Where is the NCT06646341 trial being conducted?
This trial is being conducted at Basingstoke, United Kingdom.
Who is sponsoring the NCT06646341 clinical trial?
NCT06646341 is sponsored by Imperial College London. The principal investigator is Gina Brown, MD at Imperial College London. The trial plans to enroll 100 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.